Cargando…

Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs)

[Image: see text] The class I histone deacetylase (HDAC) enzymes;HDAC1,2 and 3 form the catalytic engine of at least seven structurally distinct multiprotein complexes in cells. These molecular machines play a vital role in the regulation of chromatin accessibility and gene activity via the removal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baker, India M., Smalley, Joshua P., Sabat, Khadija A., Hodgkinson, James T., Cowley, Shaun M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910044/ https://www.ncbi.nlm.nih.gov/pubmed/35948047 http://dx.doi.org/10.1021/acs.biochem.2c00288

Ejemplares similares

Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells
por: Smalley, Joshua P., et al.
Publicado: (2022)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
por: Li, Xinyi, et al.
Publicado: (2022)

A ‘click’ chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras
por: Cross, Jasmine M., et al.
Publicado: (2022)

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
por: Khan, Sajid, et al.
Publicado: (2020)

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020)

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
por: Li, Rui, et al.
Publicado: (2022)

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
por: Li, Xin, et al.
Publicado: (2020)

Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
por: Lospinoso Severini, Ludovica, et al.
Publicado: (2022)

Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022
por: Tamatam, Rekha, et al.
Publicado: (2023)

Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity
por: Darwish, Salma, et al.
Publicado: (2022)

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
por: Moon, Yujeong, et al.
Publicado: (2023)

Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation
por: Ruffilli, Camilla, et al.
Publicado: (2022)

Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier
por: Tashima, Toshihiko
Publicado: (2023)

Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications
por: Goracci, Laura, et al.
Publicado: (2020)

A Mechanistic Pharmacodynamic Modeling Framework for the Assessment and Optimization of Proteolysis Targeting Chimeras (PROTACs)
por: Haid, Robin Thomas Ulrich, et al.
Publicado: (2023)

Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation
por: Bond, Michael J., et al.
Publicado: (2021)

The tale of proteolysis targeting chimeras (PROTACs) for Leucine‐Rich Repeat Kinase 2 (LRRK2)
por: Konstantinidou, Markella, et al.
Publicado: (2020)

MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment
por: Vicente, André T. S., et al.
Publicado: (2022)

Bifunctional HDAC Therapeutics: One Drug to Rule Them All?
por: Smalley, Joshua P., et al.
Publicado: (2020)

Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1
por: Hu, Mingxing, et al.
Publicado: (2020)

Cell Morphological Profiling Enables High-Throughput Screening for PROteolysis TArgeting Chimera (PROTAC) Phenotypic Signature
por: Trapotsi, Maria-Anna, et al.
Publicado: (2022)

Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src
por: Manda, Sudhakar, et al.
Publicado: (2020)

Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers
por: Liu, Li, et al.
Publicado: (2022)

PROTAC chemical probes for histone deacetylase enzymes
por: Patel, Urvashi, et al.
Publicado: (2023)

Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells
por: Xiao, Zhangping, et al.
Publicado: (2021)

The clinical advances of proteolysis targeting chimeras in oncology
por: Xie, Hao, et al.
Publicado: (2021)

Shining a Light on Proteolysis Targeting Chimeras
por: Teichmann, Ellen, et al.
Publicado: (2019)

Proteolysis-targeting chimeras and their implications in breast cancer
por: Tecalco-Cruz, Angeles C., et al.
Publicado: (2021)

HaloTag‐Targeted Sirtuin‐Rearranging Ligand (SirReal) for the Development of Proteolysis‐Targeting Chimeras (PROTACs) against the Lysine Deacetylase Sirtuin 2 (Sirt2)
por: Schiedel, Matthias, et al.
Publicado: (2020)

Assays and technologies for developing proteolysis targeting chimera degraders
por: Liu, Xingui, et al.
Publicado: (2020)

Computer aided drug design in the development of proteolysis targeting chimeras
por: Tunjic, Tin M., et al.
Publicado: (2023)

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
por: Lebraud, Honorine, et al.
Publicado: (2016)

Novel Design Strategies to Enhance the Efficiency of Proteolysis Targeting Chimeras
por: Zhao, Chunlong, et al.
Publicado: (2022)

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation
por: Yamanaka, Satoshi, et al.
Publicado: (2023)

Novel BET protein Proteolysis Targeting Chimera (BET-PROTAC) exerts superior lethal activity than Bromodomain Inhibitor (BETi) against post-myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells
por: Saenz, Dyana T., et al.
Publicado: (2017)

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2019)

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges
por: Wang, Chao, et al.
Publicado: (2022)

Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera
por: Kim, Kidae, et al.
Publicado: (2019)

Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery
por: Zeng, Shenxin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iqm7i8dpd0khm2kkavg1bodvnm